Lisata Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Employees: 25

Market Cap: -

Website: http://www.lisata.com

Introduction: Lisata Therapeutics, Inc. is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. It also actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

Clinical Trials

LSTA1 Phase 1b/2a Continuous Infusion Trial in MPDAC

Phase 1

Not yet recruiting

Conditions: Pancreas Cancer
Pancreatic Carcinoma
Pancreas Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Unresectable Pancreatic Cancer
Metastatic Pancreatic Cancer
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma

Interventions: Drug: LSTA1
Drug: Nab-paclitaxel
Drug: Gemcitabine
Drug: Placebo matching LSTA1

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-13

Lead Sponsor: Lisata Therapeutics, Inc.

Target Recruit Count: 30

Registration Number: NCT06592664

Locations: 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
Spartanburg Medical Center, Spartanburg, South Carolina, United States

and more 2 locations

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Phase 2

Active, not recruiting

Conditions: Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
Gall Bladder Cancer
Gallbladder Cancer
Extrahepatic Cholangiocarcinoma
Bile Duct Cancer
Gall Bladder Carcinoma
Gallbladder Carcinoma

Interventions: Drug: LSTA1
Drug: Durvalumab
Drug: FOLFOX regimen
Drug: Cisplatin
Drug: Gemcitabine
Drug: Placebo

First Posted Date: 2023-02-03

Last Posted Date: 2025-05-21

Lead Sponsor: Lisata Therapeutics, Inc.

Target Recruit Count: 67

Registration Number: NCT05712356

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States

and more 16 locations

CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

Phase 1

Completed

Conditions: Chronic Kidney Diseases

Interventions: Drug: CLBS201

First Posted Date: 2021-08-04

Last Posted Date: 2024-10-09

Lead Sponsor: Lisata Therapeutics, Inc.

Target Recruit Count: 6

Registration Number: NCT04990427

Locations: 🇺🇸
Clinical Advancement Center, PLLC, San Antonio, Texas, United States

A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

Phase 2

Terminated

Conditions: Coronary Microvascular Disease
Microvascular Coronary Artery Disease
Coronary Microvascular Dysfunction

Interventions: Biological: Placebo
Biological: CLBS16

First Posted Date: 2020-11-04

Last Posted Date: 2023-10-17

Lead Sponsor: Lisata Therapeutics, Inc.

Target Recruit Count: 34

Registration Number: NCT04614467

Locations: 🇺🇸
University of Florida - College of Medicine/ div of Cardiovascular Medicine, Gainesville, Florida, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States

and more 4 locations

CLBS119 for Repair of COVID-19 Induced Pulmonary Damage

Phase 1

Withdrawn

Conditions: Covid-19

Interventions: Biological: CLBS119

First Posted Date: 2020-08-21

Last Posted Date: 2024-10-09

Lead Sponsor: Lisata Therapeutics, Inc.

Registration Number: NCT04522817

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: CEND-1
Drug: Nab-paclitaxel
Drug: Gemcitabine

First Posted Date: 2018-05-07

Last Posted Date: 2024-08-28

Lead Sponsor: Lisata Therapeutics, Inc.

Target Recruit Count: 30

Registration Number: NCT03517176

Locations: 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺
Queen Elizabeth Hospital, Woodville South, South Australia, Australia
🇦🇺
St John of God Hospital, Subiaco, Western Australia, Australia

Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

Phase 2

Completed

Conditions: Coronary Microvascular Dysfunction

Interventions: Biological: CLBS16

First Posted Date: 2018-04-26

Last Posted Date: 2021-01-08

Lead Sponsor: Lisata Therapeutics, Inc.

Target Recruit Count: 20

Registration Number: NCT03508609

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)

Phase 2

Completed

Conditions: Diabetes Mellitus

Interventions: Biological: CLBS03 Low Dose
Biological: CLBS03 High Dose
Biological: Placebo

First Posted Date: 2016-02-25

Last Posted Date: 2021-01-08

Lead Sponsor: Lisata Therapeutics, Inc.

Target Recruit Count: 113

Registration Number: NCT02691247

Locations: 🇺🇸
University of Miami, Diabetes Research Institute, Miami, Florida, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Rady Children's Hospital, San Diego, California, United States

and more 11 locations

Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)

Phase 2

Completed

Conditions: Critical Limb Ischemia
Buerger Disease
Thromboangiitis Obliterans
Atherosclerosis Obliterans

Interventions: Biological: CLBS12
Drug: SOC

First Posted Date: 2015-07-17

Last Posted Date: 2024-10-09

Lead Sponsor: Lisata Therapeutics, Inc.

Target Recruit Count: 33

Registration Number: NCT02501018

Locations: 🇯🇵
Oita Oka Hospital, Oita, Japan
🇯🇵
Asahikawa Medical University Hospital - 1-1-1 Higashi-2jou, Midorigaoka, Asahikawa-shi, Japan
🇯🇵
Shonan Kamakura General Hospital, Kamakura, Japan

and more 9 locations

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

Phase 3

Terminated

Conditions: Stage IV Melanoma
Stage III Melanoma

Interventions: Biological: Autologous PBMCs in GM-CSF (MC)
Biological: Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)

First Posted Date: 2013-06-12

Last Posted Date: 2019-05-10

Lead Sponsor: Lisata Therapeutics, Inc.

Target Recruit Count: 4

Registration Number: NCT01875653

Home Terms & Conditions Privacy Policy